The Cooper Companies, Inc. (NASDAQ:COO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have received a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $117.00.

A number of equities analysts recently commented on the company. Morgan Stanley cut their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. Wells Fargo & Company increased their price objective on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. Citigroup dropped their target price on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, December 6th. Finally, StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th.

Cooper Companies Stock Down 1.8 %

NASDAQ:COO opened at $93.57 on Monday. Cooper Companies has a one year low of $84.76 and a one year high of $112.38. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The company has a market cap of $18.67 billion, a PE ratio of 47.98, a P/E/G ratio of 2.41 and a beta of 1.00. The firm’s 50 day simple moving average is $94.99 and its 200 day simple moving average is $99.85.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.04. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Cooper Companies’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.87 earnings per share. On average, research analysts anticipate that Cooper Companies will post 3.98 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in COO. Ashton Thomas Securities LLC bought a new position in shares of Cooper Companies in the 3rd quarter worth $25,000. Byrne Asset Management LLC acquired a new position in Cooper Companies during the fourth quarter worth $33,000. OFI Invest Asset Management bought a new position in shares of Cooper Companies in the fourth quarter valued at $34,000. Covestor Ltd grew its holdings in shares of Cooper Companies by 144.9% during the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after buying an additional 200 shares during the last quarter. Finally, Brown Brothers Harriman & Co. increased its position in shares of Cooper Companies by 191.0% during the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after acquiring an additional 275 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.